Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AGO Study Group
Carboplatin is commonly used for the treatment of ovarian cancer in first- and second-line therapy. The efficacy of gemcitabine in ovarian carcinoma was researched in various Phase 2 studies.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven ovarian cancer with evidence of recurrence or progression
Failed first-line platinum containing therapy after 6 months of treatment discontinuation
Documented lesion as evidenced by appropriate computerized tomography (CT), magnetic resonance imaging (MRI) scan, chest x-ray, or ultrasound.
Previous hormonal therapy or radiotherapy must be terminated at least 3 weeks before study drug administration
Adequate bone marrow reserve: neutrophils ≥ 1.5 x 10\^9/L and platelets ≥ 100 x 10\^9/L
You may not be if
Receiving concomitant cytotoxic or other antineoplastic treatment. Hormone replacement therapy is allowed, as are steroid antiemetics
Clinical evidence of central nervous system metastases
Active infection
Cannot adequately be followed up for the duration of the study
A second primary malignancy (except in situ carcinoma of the cervix or adequately treated basal cell carcinoma of the skin)
Use of any investigational agent in the 3 weeks prior to inclusion
Serious concomitant systematic disorders incompatible with the study
Received more than one previous chemotherapy regimen or had prior gemcitabine treatment
Patients with tumor of borderline malignancy
Patients with estimated GFR ≤ 50 mL/min
Clareo Health | Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Patients With Advanced Ovarian Cancer
